Effects of a chronic lithium treatment on central dopamine neurotransporters

Biochemical Pharmacology

Volumn 54, Issue 3, 1997, Pages 391-397

  Carli, Martin ^c   Morissette, Marc ^a   Hébert, Caroline ^c   Di Paolo, Thérèse ^a   Reader, Tomás A ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c NONE

Author keywords

Autoradiography; Dopamine; In situ hybridization; Lithium; transporters; Uptake sites

Indexed keywords

DOPAMINE TRANSPORTER; LITHIUM; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; IN SITU HYBRIDIZATION; MALE; NEOSTRIATUM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ANIMALS; AUTORADIOGRAPHY; BRAIN; CARRIER PROTEINS; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; IN SITU HYBRIDIZATION; IODINE RADIOISOTOPES; LITHIUM; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RNA, COMPLEMENTARY; RNA, MESSENGER;

EID: 0030845172     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00192-5     Document Type: Article

References (33)

1. Murphy DL, Brodie HKH, Goodwin FK and Bunney WE, Regular induction of hypomania by L-dopa in "bipolar" manic-depressive patients. Nature 229: 135-136, 1971.
2. Murphy DL, L-Dopa behavioural activation and psychopathology. Res Pub Assoc Res Nerv Ment Dis 50: 472-493, 1972.
3. Gerner RH, Post RM and Bunney WE, A dopaminergic mechanism in mania. Am J Psychiatry 133: 1177-1180, 1976.
4. Silverstone T, Response to bromocriptine distinguishes bipolar from unipolar depression. Lancet 1: 903-904, 1984.
5. Cookson JC and Silverstone T, 5-Hydroxytryptamine and dopamine pathways in mania: A pilot study of fenfluramine and pimozide. Br J Clin Pharmacol 3: 942-943, 1976.
6. Post RM, Jimerson DC, Bunney WE and Goodwin FK, Dopamine and mania: Behavioural and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology 67: 297-305, 1980.
7. Cookson J, Silverstone T and Wells B, Double-blind comparative clinical trial of pimozide and chlorpromazine in mania. A test of the dopamine hypothesis. Acta Psychiatr Scand 64: 381-397, 1981.
8. Cade JFJ, Lithium salts in the treatment of psychotic excitement. Med J Aust 36: 349-352, 1949.
9. Schou M, Normothymotics, "Mood-normalizers": Are lithium and the imipramine drugs specific for affective disorders. Br J Psychiatry 109: 803-809, 1963.
10. Prien RF, Caffey EM and Klett J, Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch Gen Psychiatry 28: 337-341, 1973.
11. Coppen A, Montgomery SA, Gupta RK and Bailey JE, A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders. Br J Psychiatry 128: 479-485, 1976.
12. Schildkraut JJ, The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 122: 509-522, 1965.
13. 3-norepinephrine metabolism in brain. Life Sci 5: 1479-1483, 1966.
14. Schorderet M, Lithium inhibition of cyclic AMP accumulation induced by dopamine in isolated retinae of the rabbit. Biochem Pharmacol 26: 167-180, 1977.
15. Gottberg E, Montreuil B and Reader TA, Acute effects of lithium on dopaminergic responses: Iontophoretic studies in the rat visual cortex. Synapse 2: 442-449, 1988.
16. Carli M, Anand-Srivastava MB, Molina-Holgado E, Dewar KM and Reader TA, Effects of chronic lithium treatments on central dopaminergic receptor systems: G proteins as possible targets. Neurochem Int 24: 13-22, 1994.
17. Giros B, El Mestikawy S, Bertrand L and Caron M, Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 295: 149-154, 1991.
18. Giros B, El Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T and Caron MG, Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42: 383-390, 1992.
19. Giros B and Caron MG, Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 14: 43-49, 1993.
20. Pifl C, Giros B and Caron MG, The cloned target site of Parkinsonism-inducing toxins and of drugs of abuse. Adv Neurol 69: 235-238, 1996.
21. 125I]iodophenyl)tropane-2β-carboxylic acid isopropyl ester. Mol Pharmacol 47: 779-786, 1995.
22. 125I]RT1-121. Synapse 21: 364-372, 1995.
23. Giros B, Jaber M, Jones SR, Wightman RM and Caron MG, Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612, 1996.
24. 3H]spiroperidol binding sites. Brain Res 267: 301-311, 1983.
25. Paxinos G and Watson C, The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney, 1982.
26. Barlow RB, Biodata Handling with Microcomputers, pp. 125-143. Elsevier Science Publishers, Amsterdam, 1983.
27. Ahluwalia P and Singhal RL, Monoamine uptake into synaptosomes from various regions of rat brain following lithium administration and withdrawal. Neuropharmacology 20: 483-487, 1981.
28. + stimulates ATP-regulated dopamine uptake in PC12 cells. Neuroscience 65: 1-4, 1995.
29. Jimerson DC, Role of dopamine mechanisms in the affective disorders. In: Psychopharmacology: The Third Generation of Progress, (Ed. Meltzer HY), pp. 505-511. Raven Publishers, New York, 1987.
30. Lapierre YD, Gagnon A and Kokkinidis L, Immediate recurrence of mania following lithium withdrawal. Biol Psychiatry 15: 859-864, 1980.
31. 1A receptors. Neurochem Res 22: 427-435, 1997.
32. Lopez-Corcuera B, Gimenez C and Aragon C, Change of synaptic membrane lipid composition and fluidity by chronic administration of lithium. Biochim Biophys Acta 939: 467-475, 1988.
33. Diehl DJ and Gershon S, The role of dopamine in mood disorders. Compr Psychiatry 33: 115-120, 1992.